HMOX1 and pancreatic neoplasm: Thus, HO-1 silencing increases the effect of chemotherapeutic drugs in pancreatic cancer [217], neuroblastoma [148,149], and melanoma cancer cells [140], as well as in myeloid leukemia [170].